Edwards Lifesciences

Q2 FY2026 EarningsQ2 FY26 revenue rose 13.6% YoY to $1.74B, surpassing expectations with 12.5% constant currency growth. TMTT sales surged 47.3% YoY to $195.9M, while TAVR reached $1.26B (+11.3% YoY), benefiting from stable pricing and competitor exits. Adjusted EPS was $0.78, beating internal targets despite a GAAP net income decline caused by a $188.2M one-time tax valuation allowance in California. Full-year FY26 sales growth guidance was raised to 10%-11%.